Brief: Adial Pharmaceuticals Awarded Notice Of Allowance For Key Patent Combining Use Of The Company’S Proprietary Genetic Diagnostic With Ad04 To Treat Alcohol And Drug Dependence
Oct 19 (Reuters) - Adial Pharmaceuticals Inc ADIL.O :
* ADIAL PHARMACEUTICALS AWARDED NOTICE OF ALLOWANCE FOR KEY
PATENT
COMBINING USE OF THE COMPANY’S PROPRIETARY GENETIC DIAGNOSTIC
WITH AD04 TO TREAT ALCOHOL AND DRUG DEPENDENCE
Source text for Eikon: ID:nGNX4n2w6T
Further company coverage: ADIL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Adial Pharmaceuticals
See all newsBrief: Adial Pharmaceuticals Announces Name Change To Azora Therapeutics
Brief: Adial Pharmaceuticals Announces Planned Appointment Of Celia Economides As Chief Financial Officer
Brief: Adial Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Brief: Adial Pharmaceuticals - Proposed Resale Of Up To 25,148,970 Shares Of Common Stock By Selling Stockholders - SEC Filing
Brief: Adial Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)